KURA: Kura Oncology, Inc.
About
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Current Value
$15.961 Year Return
Current Value
$15.961 Year Return
Key Details
Market Cap
$1.24B
P/E Ratio
-6.77
1Y Stock Return
70.88%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
2.9
Strategies that include KURA
Stock's related to KURA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CORZ | 69.59% | $4.60B | +3,201.26% | 0.00% |
| TXT | 48.08% | $15.08B | +4.50% | 0.10% |
| RYTM | 41.46% | $3.69B | +79.50% | 0.00% |
| QCRH | 40.42% | $1.51B | +75.87% | 0.27% |
| KFRC | 38.94% | $1.10B | -8.71% | 0.66% |
| GD | 38.61% | $77.26B | +14.02% | 1.98% |
| SUNS | 36.50% | $105.89M | +35.31% | 1.37% |
| ALLO | 34.10% | $444.50M | -24.82% | 0.00% |
| NVEE | 33.35% | $1.45B | -9.73% | 0.00% |
| XNCR | 33.26% | $1.65B | +27.73% | 0.00% |
| PSTX | 32.85% | $269.98M | +6.13% | 0.00% |
| RCUS | 32.26% | $1.33B | +5.07% | 0.00% |
| PRPL | 32.01% | $91.37M | +7.08% | 0.00% |
| IMAB | 31.88% | $73.40M | -37.30% | 0.00% |
| BUSE | 31.22% | $1.50B | +24.85% | 3.65% |
| ONIT | 31.22% | $240.15M | +14.44% | 0.00% |
| NRIX | 30.68% | $1.61B | +269.37% | 0.00% |
| HONE | 30.34% | $572.67M | +17.97% | 2.43% |
| TY | 30.07% | - | - | 3.32% |
| STEL | 30.04% | $1.58B | +26.76% | 1.77% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DD | -28.39% | $34.00B | +14.83% | 1.84% |
| KMB | -17.24% | $45.22B | +11.57% | 3.58% |
| CHD | -16.90% | $27.18B | +19.50% | 1.03% |
| BB | -13.63% | $1.39B | -34.90% | 0.00% |
| VZIO | -11.45% | $2.29B | +67.76% | 0.00% |
| RUM | -10.79% | $1.61B | +13.37% | 0.00% |
| PULM | -9.98% | $19.83M | +202.98% | 0.00% |
| PG | -9.39% | $402.15B | +14.14% | 2.33% |
| CTRE | -8.64% | $5.82B | +36.14% | 3.72% |
| SRAD | -8.32% | $5.18B | +75.20% | 0.00% |
| MCK | -7.44% | $78.15B | +35.51% | 0.42% |
| FATBB | -7.36% | $81.94M | -12.91% | 11.69% |
| CNK | -7.18% | $4.09B | +138.59% | 0.00% |
| OHI | -6.83% | $10.84B | +26.02% | 6.71% |
| LMT | -6.74% | $126.40B | +18.99% | 2.36% |
| FARM | -6.67% | $41.47M | -25.00% | 0.00% |
| COR | -6.54% | $47.48B | +21.20% | 0.86% |
| HUSA | -6.43% | $16.69M | -11.56% | 0.00% |
| TKO | -6.28% | $10.62B | +67.14% | 0.00% |
| CL | -6.26% | $76.48B | +22.25% | 2.12% |
ETF's related to KURA
News
SeekingAlpha
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsPete De Spain - Head, Investor...
Yahoo
Despite increased R&D costs and net loss, Kura Oncology Inc (KURA) showcases promising clinical progress and a robust financial position.
Yahoo
SAN DIEGO (AP) — Kura Oncology Inc. KURA) on Thursday reported a loss of $54.4 million in its third quarter. The San Diego-based company said it had a loss of 63 cents per share.
Yahoo
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation study of ziftomenib combined with ven/aza in R/R AML and 7+3 in 1L adverse risk AML to be presented at ASH – – Phase 1b expansion study of ziftomenib in combination with standards of care now enrolling at 600 mg in all cohorts – – Preclinical data support opportunity for ziftomenib i
Yahoo
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th – – Ziftomenib combined with ven/aza in R/R NPM1-m or KMT2A-r AML patients selected for poster presentation on Sunday, December 8th – SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced t
Yahoo
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.